{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T12:34:15Z","timestamp":1780662855177,"version":"3.54.1"},"reference-count":80,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1684\/bdc.2009.0979","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T20:01:59Z","timestamp":1565726519000},"page":"233-243","source":"Crossref","is-referenced-by-count":6,"title":["Naus\u00e9es et vomissements chimio-induits : physiopathologie, prophylaxie et recommandations"],"prefix":"10.1016","volume":"97","author":[{"given":"A.","family":"Mailliez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bonneterre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1684\/bdc.2009.0979_bib0005","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00520-001-0339-7","article-title":"Nausea and emesis: still an unsolved problem in cancer patients?","volume":"10","author":"Herrstedt","year":"2002","journal-title":"Support Care Cancer"},{"key":"10.1684\/bdc.2009.0979_bib0010","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/bjc.1997.507","article-title":"Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists","volume":"76","author":"de Boer-Dennert","year":"1997","journal-title":"Br J Cancer"},{"key":"10.1684\/bdc.2009.0979_bib0015","first-page":"44","article-title":"Ueber das Brechcentrum und \u00fcber die wirkung einiger pharmakologischer Mittel auf dasselbe","volume":"123","author":"Thumas","year":"1891","journal-title":"Archieves f\u00fcr Pathologische Anatomie"},{"key":"10.1684\/bdc.2009.0979_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0016-5085(19)36357-7","article-title":"A new concept of organization of the central emetic mechanism: recent studies on the sites of action of apomorphine, copper sulfate and cardiac glycosides","volume":"22","author":"Wang","year":"1952","journal-title":"Gastroenterology"},{"key":"10.1684\/bdc.2009.0979_bib0025","first-page":"193","article-title":"Physiology and pharmacology of vomiting","volume":"5","author":"Borison","year":"1953","journal-title":"Pharmacol Rev"},{"key":"10.1684\/bdc.2009.0979_bib0030","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ejca.2004.09.026","article-title":"Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment","volume":"41","author":"Jordan","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1684\/bdc.2009.0979_bib0035","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00520-004-0745-8","article-title":"Anticipatory nausea and vomiting","volume":"13","author":"Aapro","year":"2005","journal-title":"Support Care Cancer"},{"key":"10.1684\/bdc.2009.0979_bib0040","first-page":"116","article-title":"Determinants of postchemotherapy nausea and vomiting in patients with cancer","volume":"15","author":"Osoba","year":"1997","journal-title":"Quality of life and symptom control committees of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol"},{"key":"10.1684\/bdc.2009.0979_bib0045","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s00520-004-0718-y","article-title":"Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-an update","volume":"13","author":"Grunberg","year":"2005","journal-title":"Support Care Cancer"},{"key":"10.1684\/bdc.2009.0979_bib0050","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1126\/science.108.2804.329","article-title":"Crystalline serotonin","volume":"24","author":"Rapport","year":"1948","journal-title":"Science"},{"key":"10.1684\/bdc.2009.0979_bib0055","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1476-5381.1957.tb00142.x","article-title":"Two kinds of tryptamine receptor","volume":"12","author":"Gadum","year":"1957","journal-title":"Br J Pharmacol Chemother"},{"key":"10.1684\/bdc.2009.0979_bib0060","first-page":"687","article-title":"Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol","volume":"16","author":"Peroutka","year":"1979","journal-title":"Mol Pharmacol"},{"key":"10.1684\/bdc.2009.0979_bib0065","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0014-2999(78)90228-5","article-title":"Blockade of neuronal tryptamine receptors by metoclopramide","volume":"49","author":"Fozard","year":"1978","journal-title":"Eur J Pharmacol"},{"key":"10.1684\/bdc.2009.0979_bib0070","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM198110153051601","article-title":"Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting","volume":"305","author":"Gralla","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2009.0979_bib0075","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/S0140-6736(87)92159-3","article-title":"First results with ICS 205-930 (5-HT3 receptor antagonist) in prevention of chemotherapy-induced emesis","volume":"1","author":"Leibundgut","year":"1987","journal-title":"Lancet"},{"key":"10.1684\/bdc.2009.0979_bib0080","first-page":"577","article-title":"An unidentified depressor substance in certain tissue extracts","volume":"72","author":"Von Euler","year":"1931","journal-title":"J Physiol (Lond)"},{"key":"10.1684\/bdc.2009.0979_bib0085","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1016\/S0021-9258(18)62860-1","article-title":"Isolation of a sialogogic peptide from bovine hypothalamic tissue and its characterization as substance P","volume":"245","author":"Chang","year":"1970","journal-title":"J Biol Chem"},{"key":"10.1684\/bdc.2009.0979_bib0090","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/294467a0","article-title":"A specific substance P antagonist blocks smooth muscle contractions induced by non-cholinergic, non-adrenergic nerve stimulation","volume":"294","author":"Leander","year":"1981","journal-title":"Nature"},{"key":"10.1684\/bdc.2009.0979_bib0095","doi-asserted-by":"crossref","first-page":"R5","DOI":"10.1016\/0014-2999(93)90649-3","article-title":"The tachykinin NK1 receptor antagonist CP-99,994 attenuates cisplatin induced emesis in the ferret","volume":"250","author":"Tattersall","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"10.1684\/bdc.2009.0979_bib0100","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/jnci\/89.11.817","article-title":"Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin","volume":"89","author":"Kris","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"10.1684\/bdc.2009.0979_bib0105","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/0959-8049(95)00192-L","article-title":"Comparison of granisetron alone and granisetron plus hydroxyzine hydrochloride for prophylactic treatment of emesis induced by cisplatin chemotherapy","volume":"31A","author":"Tsukuda","year":"1995","journal-title":"Eur J Cancer"},{"key":"10.1684\/bdc.2009.0979_bib0110","first-page":"1975","article-title":"Results of a randomized double blind crossover trial of scopolamine versus placebo administered by transdermal patch for the control of cisplatin-induced emesis","volume":"66","author":"Longo","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"10.1684\/bdc.2009.0979_bib0115","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1200\/JCO.2003.01.095","volume":"21","author":"Hesketh","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2009.0979_bib0120","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1056\/NEJM197909273011318","article-title":"Nabilone as an antiemetic","volume":"301","author":"Baker","year":"1979","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2009.0979_bib0125","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1136\/bmj.289.6449.878-a","article-title":"Dexamethasone and high-dose metoclopramide: efficacy in controlling cisplatin induced nausea and vomiting","volume":"289","author":"Allan","year":"1984","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1684\/bdc.2009.0979_bib0130","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1200\/JCO.1991.9.4.675","article-title":"Prevention of cisplatin-induced emesis: a double blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone","volume":"9","author":"Roila","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2009.0979_bib0135","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1056\/NEJM199304153281502","article-title":"Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy","volume":"328","author":"Herrstedt","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2009.0979_bib0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199501053320101","article-title":"Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer","volume":"332","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2009.0979_bib0145","first-page":"3090","article-title":"Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting","volume":"97","author":"Poli-Bigelli","year":"2003","journal-title":"Results from a randomized, double blind, placebo-controlled trial in Latin America. Cancer"},{"key":"10.1684\/bdc.2009.0979_bib0150","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1200\/JCO.2005.09.050","article-title":"Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy","volume":"23","author":"Warr","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2009.0979_bib0155","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.critrevonc.2006.08.003","article-title":"Comparative activity of antiemetic drugs","volume":"61","author":"Jordan","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1684\/bdc.2009.0979_bib0160","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1056\/NEJM197909273011318","article-title":"Nabilone as an antiemetic","volume":"301","author":"Baker","year":"1979","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2009.0979_bib0165","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s005200050155","article-title":"Corticosteroids, dopamine antagonists and other drugs","volume":"6","author":"Herrstedt","year":"1998","journal-title":"Support Care Cancer"},{"key":"10.1684\/bdc.2009.0979_bib0170","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/00000421-198510000-00016","article-title":"Dexamethasone vs placebo for cisplatin-induced emesis","volume":"8","author":"Dana","year":"1985","journal-title":"A randomized crossover trial. Am J Clin Oncol"},{"key":"10.1684\/bdc.2009.0979_bib0175","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1200\/JCO.2000.18.19.3409","article-title":"Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence","volume":"18","author":"Ioannidis","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2009.0979_bib0180","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/annonc\/mdg075","article-title":"A randomized double blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis","volume":"14","author":"Aapro","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2009.0979_bib0185","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1056\/NEJM200005253422102","article-title":"Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy","volume":"342","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2009.0979_bib0190","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1002\/cncr.11320","article-title":"Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting","volume":"97","author":"Chawla","year":"2003","journal-title":"Cancer"},{"key":"10.1684\/bdc.2009.0979_bib0195","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1200\/JCO.1998.16.9.2937","article-title":"Double blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis","volume":"16","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2009.0979_bib0200","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1200\/JCO.2004.09.040","article-title":"Randomized, double blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide","volume":"22","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2009.0979_bib0205","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1200\/JCO.1990.8.6.1063","article-title":"A randomized double blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy","volume":"8","author":"Bonneterre","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2009.0979_bib0210","first-page":"311","article-title":"A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double blind study","volume":"26","author":"Kaasa","year":"1990","journal-title":"International Emesis Study Group. Eur J Cancer"},{"key":"10.1684\/bdc.2009.0979_bib0215","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/0140-6736(91)90554-3","article-title":"Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy","volume":"338","author":"Jones","year":"1991","journal-title":"Lancet"},{"key":"10.1684\/bdc.2009.0979_bib0220","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1200\/JCO.2005.04.022","article-title":"Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications","volume":"23","author":"Geling","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2009.0979_bib0225","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1200\/JCO.1997.15.1.124","article-title":"Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis","volume":"15","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2009.0979_bib0230","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00520-001-0335-y","article-title":"Antiemetic guidelines: creating a more practical treatment approach","volume":"10","author":"Koeller","year":"2002","journal-title":"Support Care Cancer"},{"key":"10.1684\/bdc.2009.0979_bib0235","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1200\/JCO.2006.06.9591","article-title":"American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006","volume":"24","author":"Kris","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2009.0979_bib0240","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1634\/theoncologist.7-5-424","article-title":"5-HT(3)-receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profile","volume":"7","author":"Goodin","year":"2002","journal-title":"Oncologist"},{"key":"10.1684\/bdc.2009.0979_bib0245","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/annonc\/mdg417","article-title":"Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double blind randomized phase III trial comparing single doses of palonosetron with ondansetron","volume":"14","author":"Gralla","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2009.0979_bib0250","first-page":"2473","article-title":"99-04 Palonosetron Study Grou","volume":"98","author":"Eisenberg","year":"2003","journal-title":"Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer"},{"key":"10.1684\/bdc.2009.0979_bib0255","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/annonc\/mdl137","article-title":"A phase III, double blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy","volume":"17","author":"Aapro","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2009.0979_bib0260","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(08)70313-9","article-title":"Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double blind, double dummy, randomised, comparative phase III trial","volume":"10","author":"Saito","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1684\/bdc.2009.0979_bib0265","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0959-8049(00)00416-0","article-title":"Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis","volume":"37","author":"Cocquyt","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1684\/bdc.2009.0979_bib0270","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1002\/cncr.10516","article-title":"Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869","volume":"94","author":"Van Belle","year":"2002","journal-title":"Cancer"},{"key":"10.1684\/bdc.2009.0979_bib0275","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1200\/JCO.2001.19.6.1759","article-title":"Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone","volume":"19","author":"Campos","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2009.0979_bib0280","first-page":"190","article-title":"Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist","volume":"340","author":"Navari","year":"1999","journal-title":"L-754,030 Antiemetic Trials Group. N Engl J Med"},{"key":"10.1684\/bdc.2009.0979_bib0285","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/annonc\/mdl019","article-title":"Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment","volume":"17","author":"Schmoll","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2009.0979_bib0290","first-page":"141","article-title":"Aprepitant for the prevention of cisplatine induced nausea and vomiting: an observational study","volume":"96","author":"Galy","year":"2009","journal-title":"Bull Cancer"},{"key":"10.1684\/bdc.2009.0979_bib0295","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ejca.2003.08.028","article-title":"The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials","volume":"40","author":"de Wit","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1684\/bdc.2009.0979_bib0300","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/cncr.21343","article-title":"Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy","volume":"104","author":"Herrstedt","year":"2005","journal-title":"Cancer"},{"key":"10.1684\/bdc.2009.0979_bib0305","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/ncponc1021","article-title":"Antiemetics: an update and the MASCC guidelines applied in clinical practice","volume":"5","author":"Herrstedt","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1684\/bdc.2009.0979_bib0310","series-title":"Bull Cancer","article-title":"Guidelines for prophylaxis and treatment of chemotherapy-induced nausea and vomiting","author":"Durand","year":"2009"},{"key":"10.1684\/bdc.2009.0979_bib0315","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00280-004-0946-3","article-title":"Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients","volume":"55","author":"Nygren","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1684\/bdc.2009.0979_bib0320","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00280-006-0359-6","article-title":"Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients","volume":"59","author":"Loos","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1684\/bdc.2009.0979_bib0325","volume":"24","author":"Arpornwirat","year":"2006","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1684\/bdc.2009.0979_bib0330","article-title":"Randomized phase II trial of the neurokinin-1 receptor antagonist (NK1-RA) casopitant mesylate with ondansetron (ond)\/dexamethasone (DXM) for chemotherapy-induced nausea\/vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC)","volume":"24","author":"Rolski","year":"2006","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1684\/bdc.2009.0979_bib0335","unstructured":"A Study of the drug casopitant for the prevention of nausea caused by cisplatin-based highly emetogenic chemotherapy. Clinicaltrials.gov 2008 May 12."},{"key":"10.1684\/bdc.2009.0979_bib0340","unstructured":"Intravenous and oral casopitant (GW679769) for the prevention of chemotherapy induced nausea and vomiting. Clinicaltrials.gov 2008 May 13."},{"key":"10.1684\/bdc.2009.0979_bib0345","unstructured":"A study of IV casopitant for the prevention of chemotherapy induced nausea and vomiting. Clinicaltrials.gov 2008 May 13."},{"key":"10.1684\/bdc.2009.0979_bib0350","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s005200100288","article-title":"Perugia Consensus; Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). How do we manage patients with refractory or breakthrough emesis?","volume":"10","author":"Aapro","year":"2002","journal-title":"Support Care Cancer"},{"key":"10.1684\/bdc.2009.0979_bib0355","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","article-title":"Radioreceptor binding profile of the atypical antipsychotic olanzapine","volume":"14","author":"Bymaster","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1684\/bdc.2009.0979_bib0360","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0885-3924(02)00381-0","article-title":"An open-label, crossover trial of mirtazapine (15 and 30mg) in cancer patients with pain and other distressing symptoms","volume":"23","author":"Theobald","year":"2002","journal-title":"J Pain Symptom Manage"},{"key":"10.1684\/bdc.2009.0979_bib0365","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00520-007-0248-5","article-title":"A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group Study","volume":"15","author":"Navari","year":"2007","journal-title":"Support Care Cancer"},{"key":"10.1684\/bdc.2009.0979_bib0370","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00520-004-0755-6","article-title":"A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study","volume":"13","author":"Navari","year":"2005","journal-title":"Support Care Cancer"},{"key":"10.1684\/bdc.2009.0979_bib0375","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00520-004-0741-z","article-title":"Midazolam for acute emesis refractory to dexamethasone and granisetron after highly emetogenic chemotherapy: a phase II study","volume":"13","author":"Mandal\u00e0","year":"2005","journal-title":"Support Care Cancer"},{"key":"10.1684\/bdc.2009.0979_bib0380","first-page":"163","article-title":"Antiemetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol","volume":"68","author":"Gralla","year":"1984","journal-title":"Cancer Treat Rep"},{"key":"10.1684\/bdc.2009.0979_bib0385","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.1999.17.9.2971","article-title":"Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines","volume":"17","author":"Gralla","year":"1999","journal-title":"American Society of Clinical Oncology. J Clin Oncol"},{"key":"10.1684\/bdc.2009.0979_bib0390","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/annonc\/mdj078","article-title":"Antiemetic Subcommitte of the Multinational Association of Supportive Care in Cancer. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference","volume":"17","author":"Roila","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2009.0979_bib0395","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncolgy: Antiemesis, V.1.2007."},{"issue":"Suppl 2","key":"10.1684\/bdc.2009.0979_bib0400","doi-asserted-by":"crossref","first-page":"ii83","DOI":"10.1093\/annonc\/mdm050","article-title":"Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis","volume":"18","author":"Herrstedt","year":"2007","journal-title":"Ann Oncol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115308869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115308869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,25]],"date-time":"2022-09-25T16:14:45Z","timestamp":1664122485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455115308869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":80,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S0007455115308869"],"URL":"https:\/\/doi.org\/10.1684\/bdc.2009.0979","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}